NEW YORK, NY--(Marketwired - January 20, 2015) - Plandaí Biotechnology (OTCQB: PLPL) proved in a bioavailability study performed at North West University in South Africa, that its green tea Phytofare® Catechin Complex demonstrates ten times greater bioavailability over that of a generic catechin extract. Bioavailability is a fancy word for how much of the dosage of a drug or substance like Plandaí's extract gets absorbed into our bloodstream so it can actually be effective. The three-part human clinical trial proved in part two of the study that all 8 catechins that make up the green tea plant made it into the bloodstream of the 26 participants, and those catechins stayed in the bloodstream 5 times longer than the generic extract that Plandaí's product was compared to in the study.
Now imagine taking a product that demonstrates it is highly bioavailable and then making it even stronger. That is Plandaí's plan with the addition of the Pheroid® delivery system. Think of the Pheroid technology, developed by Professor Anne Grobler at North West University, as a "Trojan Horse" sneaking Plandaí's highly bioavailable extract even deeper into the human body, not just into the bloodstream, but into our cells.
We've all heard of the many benefits that the green tea plant provides, but those benefits can only be realized if the catechins that make up the plant can get into the bloodstream and stay there long enough to be effective, and now Plandaí is talking about potentially making the benefits of green tea even more powerful by delivering the company's extract right to the cells of the human body.
This month Plandaí expects to begin what will be the third arm of the three-part human clinical trial. The research team at North West University, under the supervision of the Dean's office of the Faculty of Health Sciences and Prof. Anne Grobler, will complete this third arm of the bioavailability study. This final phase, which will use the same 26 participants as parts 1 and 2, will incorporate the addition of Pheroid to Plandaí's Phytofare extract.
Plandaí Biotechnology's CEO, Roger Duffield, said of the addition of Pheroid, "Pheroid is an amazing delivery system that protects the entrapped Phytofare from damage. When dealing with nutraceutical ingredients and additives, small things can have a huge impact on viability. Exposure to heat, light, and air during the processing and storage can affect the potency. Other ingredients, such as sugar, water, preservatives and the like can neutralize the active properties. And the digestive process itself is designed to break down and metabolize the catechin molecules, potentially ruining their efficacy."
So what makes Pheroid the ideal way to deliver Plandaí's extracts into the cells of the body? Pheroid uses a long-chain Omega-3 and Omega-6 fatty acid system to entrap the company's Phytofare at the mainly nano level. Our white blood cells perceive the fatty acids as a food source and bring them inside the cells, where the process of glycolysis dissolves the Pheroid and releases Phytofare. This will increase Plandaí's ability to deliver active ingredients directly to the cells.
Duffield added, "Using Pheroid allows us to expand the potential applications of Phytofare. The protective barrier provided by Pheroid gives customers the ability to add it to a host of different ingredients that would otherwise impact the product's efficacy. Pheroid's protective properties also mean that customers have greater flexibility in their manufacturing and packaging. Finally, from an application standpoint, using Pheroid opens the door for both topical and liquid oral products."
Having a Pheroid alternative for Plandaí's customers opens a host of additional product options for the company. For example, topical creams and liquid oral products are ideal for Pheroid as it protects the Phytofare and also facilitates absorption. (Pharmaceutical applications of Pheroid technology / Anne F. Grobler Abstract 2009: http://hdl.handle.net/10394/6701) Duffield said that the company's customers can then also add ingredients such as flavor enhancements, fragrance, coloring, or other active ingredients without causing interactions that could neutralize Phytofare's effectiveness.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. SMMG is compensated $3,500 per month by Plandai Biotechnology for content development. Previously, SMMG was compensated for similar content by a third party which occurred from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its content. Neither SMMG nor anyone associated with it owns shares in PLPL. For more information: www.stockmarketmediagroup.com.